EARLY BIRD REGISTRATION ENDS SEPTEMBER 1!
![shutterstock_2658171737 [Converted]_Smaller.jpg](https://static.wixstatic.com/media/dcb143_8063f21dfa5b4fe6890ff40ca69c3d51~mv2.jpg/v1/fill/w_147,h_49,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/dcb143_8063f21dfa5b4fe6890ff40ca69c3d51~mv2.jpg)
Member Spotlight
Knell Villarta, PA-C
Knell Villarta, PA-C, serves as the Lead Advanced Practice Provider at International Spine, Pain and Performance Center in Washington, D.C., and Arlington, Virginia. His passion for pain management began while working as a medical assistant in interventional pain management prior to PA school, leading him to pursue a career dedicated to advancing patient care. Knell is committed to evidence-based, patient-centered treatment plans that range from conservative therapies to interventional and surgical management when appropriate. Outside of work, he enjoys following sports, exploring new restaurants, and spending time with his wife and their dog, Ember.
.png)
INDUSTRY NEWS
Will recent FDA approval of a novel
nonopioid analgesic be a game changer?
Physician's Weekly
The Food and Drug Administration recently approved Journavx, a first-in-class oral, nonopioid, highly selective sodium channel blocker indicated as a treatment for adults with moderate to severe acute pain. Clinical data revealed that this agent is an effective, well-tolerated medicine without evidence of addictive potential, indicated for use with all types of moderate to sever acute pain.
